Top 10, the best-selling drug in 2024, predicts that K medicine will take the place of Sumeria to become the champion

World preview 2019, outlook to 2024, a report released by evaluatepharma, the world's leading pharmaceutical market research organization, points out that the global prescription drug sales are expected to reach $1.18 trillion in 2024 During the forecast period (2019-2024), the market is expected to grow at a CAGR of 6.9%, significantly higher than the 2.3% in 2010-2018 In the forecast period, the global orphan drug market will double, with sales of US $130 billion in 2018 and US $239 billion in 2024 Oncology will continue to lead the major treatment areas, with a rapid growth of + 11.4% CAGR in the forecast period It is expected that the global sales will reach $236.6 billion in 2024, which will exceed the sum of the next three treatment areas (diabetes + rheumatoid + vaccine, a total of $167 billion) In addition to oncology, the largest CAGR of the 15 treatment categories will come from immunosuppressants (+ 16.9%), skin drugs (+ 12.6%) and anti hyperlipidemic drugs (+ 10.8%) Due to the impact of the patent cliff, it is estimated that there will be $1980 billion of sales in the forecast period, which will face the risk of generic competition In particular, the anti rheumatoid market is expected to decline by - 1.0% CAGR in the forecast period, and the sales volume in 2024 will drop to US $54.6 billion, due to the competition of Biomimetic Drugs for Humira, Enbrel and REMICADE Also affected by generic competition, the multiple sclerosis market is expected to decline by - 1.2% CAGR in the forecast period These two markets are the only two of the 15 treatment categories in the forecast period where sales are expected to decline In the report, evaluatepharma analysts also predicted the top 10 drugs in 2024 According to the report, Humira, the flagship product of Aberdeen, has long been the best-selling drug in the world However, with the increasing competition for bio generic drugs, keytruda, a cancer immunotherapy from MSD, will replace Humira as the best-selling drug in the world by 2024 The reason is that keytruda has accumulated a large number of new indications and rapidly entered into new treatment fields since it was approved for the first time in 2014, and has successfully defeated opdivo, a similar competitor of Bristol Myers Squibb However, in the U.S market, Humira will maintain its dominant position in the forecast period due to the postponement of bio generic competition to 2023 At present, Humira is facing the competition of bio generic drugs outside the United States (especially in Europe), which is one of the key reasons why keytruda can surpass Humira to become the first product in global sales According to the report, keytruda's global sales will climb to $17 billion in 2024, while Humira will fall to $12.4 billion, ranking second However, imbruvica, the blood cancer drug, and the new drugs launched in 2019 will have the opportunity to make up for the loss of Humira's sales caused by the competition of bio generic drugs According to the report, the top five drugs, followed by keytruda and Humira, will be Pfizer's and Bristol Myers Squibb's anticoagulant eliquis (No 3, $12 billion), Bristol Myers Squibb's tumor immunotherapy opdivo (No 4, $11.3 billion), Alberta and Johnson & Johnson's blood cancer drug imbruvica (No 5, $9.5 billion) The report also predicted that Pfizer's breast cancer drug ibrance will occupy the sixth place with a sales volume of $9.1 billion, while Bristol Myers Squibb Howe will spend $74 billion to acquire Revlimid, the heavyweight product obtained by new base, which will rank seventh with $8 billion, which also enables Bristol Myers Squibb to obtain three seats in the first seven drugs The remaining three drugs in the top 10 list are J & J's immunologic drug stellara (8th, US $7.8 billion), Bayer's ophthalmic drug eyla (9th, US $7.3 billion) and Gilead's latest product biktarvy (10th, US $7 billion) in the HIV franchise In particular, biktarvy is the latest product on the list, with the fastest growth rate among the top 10 drugs The sales volume of biktarvy in 2018 has reached US $1.18 billion, and the average growth rate is expected to reach 34.4% in the next five years Reference sources: 1 Move aside, Humira Merck's keytruda will capture industry's top sales spot in 2024: report2 World preview 2019, outlook to 2024